Richard Pazdur testifies during a Food and Drug Administration hearing in Silver Spring, Maryland, in June 2011. Joshua Roberts/Bloomberg/Getty Images/File

Food and Drug Administration Commissioner Marty Makary is under renewed scrutiny by Trump officials amid continued turmoil at the agency, including a series of high-profile departures that have raised questions in the administration about Makary’s ability to lead, according to two people familiar with conversations.

The pending exit of Dr. Richard Pazdur, a veteran researcher who pioneered the FDA’s approach to cancer treatments, has caused the most concern, sources say. Pazdur plans to retire this month just weeks after accepting a role heading the FDA’s largest division overseeing prescription drugs, over-the-counter medicines a

See Full Page